Peng Yan-Chih, Liao Sih-Han, Tsai Jia-Huei, Chen Po-Ting, Chang Chin-Chen, Kao Jia-Horng, Liu Kao-Lang
Department of Medical Imaging, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan.
Section of Gastroenterology, Department of Internal Medicine, National Taiwan University Cancer Center, Taipei, Taiwan.
J Formos Med Assoc. 2025 Aug;124(8):724-730. doi: 10.1016/j.jfma.2024.08.011. Epub 2024 Aug 14.
BACKGROUND/PURPOSE: Lymphoepithelioma-like cholangiocarcinoma (LELCC) is a rare variant of intrahepatic cholangiocarcinoma (ICC). We aim to analyze the differences in the clinical and radiological features of LELCC and ICC.
Between January 2003 and December 2019, a total of 21 patients diagnosed with LELCC were retrospectively enrolled, and 84 patients with ICC were selected through propensity score matching by sex, age, and initial cancer stage. The clinical characteristics, pathological findings, and radiological features were analyzed. The differences in overall survival (OS) between LELCC and ICC were evaluated using the Kaplan-Meier method.
The serum carbohydrate antigen 19-9 (CA 19-9) level was higher in the ICC group than in the LELCC group (77.9 vs 30.0 U/mL, p = 0.004). Non-rim arterial phase hyperenhancement (47.1% vs 13.7%, p = 0.005) and portovenous washout (35.3% vs 4.1%, p = 0.001) were more frequently observed in the LELCC group than in the ICC group. Intrahepatic duct dilatation was a distinct feature of the ICC group. The 5-year OS rates in the LELCC and ICC groups were 69.3% and 58.2%, respectively (p = 0.047). The 5-year OS of patients with stages I and II LELCC between ICC were not significantly different (90.0% vs 83.4%, p = 0.464). However, the 5-year OS of patients with stages III and IV LELCC was more favorable than that of patients with ICC (29.2% vs 23.0%, p = 0.017).
LELCC had a favorable outcome and several different clinicoradiological features compared with ICC.
背景/目的:淋巴上皮瘤样胆管癌(LELCC)是肝内胆管癌(ICC)的一种罕见变体。我们旨在分析LELCC和ICC在临床及影像学特征上的差异。
回顾性纳入2003年1月至2019年12月期间共21例诊断为LELCC的患者,并通过倾向评分匹配法按性别、年龄和初始癌症分期选取84例ICC患者。分析临床特征、病理结果和影像学特征。采用Kaplan-Meier法评估LELCC和ICC之间总生存期(OS)的差异。
ICC组血清糖类抗原19-9(CA 19-9)水平高于LELCC组(77.9对30.0 U/mL,p = 0.004)。与ICC组相比,LELCC组更常观察到非边缘动脉期强化(47.1%对13.7%,p = 0.005)和门静脉期廓清(35.3%对4.1%,p = 0.001)。肝内胆管扩张是ICC组的一个显著特征。LELCC组和ICC组的5年OS率分别为69.3%和58.2%(p = 0.047)。LELCC和ICC的I期和II期患者的5年OS无显著差异(90.0%对83.4%,p = 0.464)。然而,LELCC的III期和IV期患者的5年OS比ICC患者更有利(29.2%对23.0%,p = 0.017)。
与ICC相比,LELCC预后良好且具有一些不同的临床影像学特征。